Journey Medical (NASDAQ:DERM) Releases Earnings Results, Misses Expectations By $0.03 EPS

Journey Medical (NASDAQ:DERM) issued its quarterly earnings data on Thursday. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03), FiscalAI reports. The firm had revenue of $18.97 million during the quarter, compared to analyst estimates of $20.32 million. Journey Medical had a negative return on equity of 20.23% and a negative net margin of 8.95%.

Journey Medical Stock Performance

Shares of DERM traded down $0.05 during trading hours on Thursday, reaching $4.39. 180,500 shares of the company traded hands, compared to its average volume of 212,686. The stock’s fifty day moving average is $6.03 and its 200 day moving average is $6.51. The stock has a market cap of $123.89 million, a P/E ratio of -19.95 and a beta of 1.14. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.41 and a current ratio of 1.59. Journey Medical has a 1-year low of $4.25 and a 1-year high of $9.56.

Wall Street Analysts Forecast Growth

DERM has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Journey Medical in a research note on Monday, October 26th. B. Riley Financial restated a “buy” rating and set a $15.00 price target (up from $12.00) on shares of Journey Medical in a report on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Journey Medical in a report on Thursday, October 15th. Finally, Wall Street Zen downgraded Journey Medical from a “buy” rating to a “hold” rating in a research report on Saturday, October 17th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $14.00.

Journey Medical Company Profile

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and marketing prescription treatments for dermatological conditions. Founded in 2014 and based in Scottsdale, Arizona, the company primarily serves the U.S. market. Its portfolio includes treatments for conditions such as acne, rosacea, excessive underarm sweating and fungal skin infections. Products include Amzeeq and Zilxi, topical minocycline therapies; Qbrexza, a topical treatment for primary axillary hyperhidrosis; and the oral rosacea treatment Emrosi.